NO20010920L - Stabil hypoksi induserbar faktor-1<alfa> og anvendelsesmetoder - Google Patents

Stabil hypoksi induserbar faktor-1<alfa> og anvendelsesmetoder

Info

Publication number
NO20010920L
NO20010920L NO20010920A NO20010920A NO20010920L NO 20010920 L NO20010920 L NO 20010920L NO 20010920 A NO20010920 A NO 20010920A NO 20010920 A NO20010920 A NO 20010920A NO 20010920 L NO20010920 L NO 20010920L
Authority
NO
Norway
Prior art keywords
alpha
inducible factor
hypoxia
mutein
stable
Prior art date
Application number
NO20010920A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010920D0 (no
Inventor
Gregg L Semenza
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Publication of NO20010920D0 publication Critical patent/NO20010920D0/no
Publication of NO20010920L publication Critical patent/NO20010920L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Manufacturing Of Steel Electrode Plates (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20010920A 1998-08-25 2001-02-23 Stabil hypoksi induserbar faktor-1<alfa> og anvendelsesmetoder NO20010920L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/148,547 US6124131A (en) 1998-08-25 1998-08-25 Mutant hypoxia inducible factor-1 HIF-1
PCT/US1999/019416 WO2000010578A1 (en) 1998-08-25 1999-08-25 STABLE HYPOXIA INDUCIBLE FACTOR-1 alpha AND METHOD OF USE

Publications (2)

Publication Number Publication Date
NO20010920D0 NO20010920D0 (no) 2001-02-23
NO20010920L true NO20010920L (no) 2001-04-23

Family

ID=22526230

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010920A NO20010920L (no) 1998-08-25 2001-02-23 Stabil hypoksi induserbar faktor-1<alfa> og anvendelsesmetoder

Country Status (11)

Country Link
US (3) US6124131A (de)
EP (1) EP1107768B1 (de)
JP (1) JP2002523028A (de)
AT (1) ATE344043T1 (de)
AU (1) AU758627B2 (de)
CA (1) CA2340328C (de)
DE (1) DE69933877T2 (de)
IL (2) IL141494A0 (de)
NO (1) NO20010920L (de)
NZ (1) NZ510002A (de)
WO (1) WO2000010578A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136454A0 (en) * 1997-12-04 2001-06-14 Genzyme Corp Compositions and methods for inducing gene expression
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1
FR2801319A1 (fr) * 1999-11-18 2001-05-25 Inst Nat Sante Rech Med Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene
AU2001290179B2 (en) * 2000-08-07 2007-07-12 Angiogenetics Sweden Ab Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
US6849718B2 (en) * 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
US7247620B2 (en) 2001-05-09 2007-07-24 Anges Mg, Inc. Method of treating skin wounds with vectors encoding hepatocyte growth factor
WO2002094862A2 (en) * 2001-05-23 2002-11-28 Angiogene Inc. Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
US6838430B2 (en) 2001-09-28 2005-01-04 The Regents Of The University Of California Use of HIF-1a variants to accelerate wound healing
US20030093147A1 (en) * 2001-11-13 2003-05-15 Ogle Matthew F. Medical devices that stimulate growth factor production
CA3094774A1 (en) * 2001-12-06 2003-07-03 Fibrogen, Inc. Use of hif prolyl hydroxylase inhibitors for treating neurological disorders
US7053046B2 (en) * 2001-12-21 2006-05-30 Mcgrath Kevin Peptide activators of VEGF
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CN101518535A (zh) * 2002-12-06 2009-09-02 法布罗根股份有限公司 脂肪调节
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2005037217A2 (en) * 2003-10-17 2005-04-28 Actis Biologics, Inc. Lentiviral vector delivery of msp36 for treatment of cancer
WO2005094236A2 (en) * 2003-11-07 2005-10-13 Henry M. Jackson Foundation Activation of hypoxia-inducible gene expression
US20050148496A1 (en) * 2003-11-26 2005-07-07 Entelos, Inc. Treatment of rheumatoid arthritis with hypoxia inducible factor-1alpha antagonists
US20050137568A1 (en) * 2003-12-17 2005-06-23 Jones Donald K. Activatable bioactive implantable medical device and method of use
US7294123B2 (en) * 2003-12-17 2007-11-13 Corris Neurovascular, Inc. Activatable bioactive vascular occlusive device and method of use
CN1980573A (zh) * 2003-12-31 2007-06-13 艾克蒂斯生物公司 用于治疗癌症的天然和突变igfbp－3的慢病毒载体传送
US7247159B2 (en) * 2004-04-08 2007-07-24 Cordis Neurovascular, Inc. Activatable bioactive vascular occlusive device
US20060003961A1 (en) * 2004-06-18 2006-01-05 The John Hopkins University Negative regulation of hypoxia inducible factor 1 by OS-9
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇－海藻酸钠微球血管栓塞剂及其制备
US20090304650A1 (en) * 2005-05-11 2009-12-10 Scott Edward W Repair of the Bone Marrow Vasculature
AU2006259352A1 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of HIF 1alfa modulators for treatment of cancer
GB0520176D0 (en) * 2005-10-04 2005-11-09 Imp College Innovations Ltd Use
WO2007048004A2 (en) 2005-10-21 2007-04-26 Cornell Research Foundation, Inc. Compounds for enhancing hypoxia inducible factor activity and methods of use
BRPI0710048A2 (pt) * 2006-03-30 2011-08-02 Lg Electronics Inc método e aparelho para decodificar / codificar um sinal de vìdeo
US7759306B2 (en) * 2006-05-16 2010-07-20 Simoni Jan S Methods of treating acute blood loss
KR20090038921A (ko) 2006-07-31 2009-04-21 바스큘라 바이오제닉스 리미티드 허혈 관련 의학적 증상을 치료하는 폴리펩타이드, 이를 암호화하는 폴리뉴클레오타이드, 및 이의 치료 용도
US20080081354A1 (en) * 2006-10-02 2008-04-03 Cardiac Pacemakers, Inc. Devices, vectors and methods for inducible ischemia cardioprotection
HUE031182T2 (en) 2006-10-03 2017-06-28 Genzyme Corp Gene therapy for spinal muscle atrophy
KR100992526B1 (ko) * 2007-11-21 2010-11-05 한국과학기술연구원 이황화결합을 이용한 내열성의 알파-1-안티트립신 뮤테인및 그의 제조방법
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
WO2017027810A2 (en) * 2015-08-12 2017-02-16 The General Hospital Corporation Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
US6099832A (en) * 1997-05-28 2000-08-08 Genzyme Corporation Transplants for myocardial scars
IL136454A0 (en) * 1997-12-04 2001-06-14 Genzyme Corp Compositions and methods for inducing gene expression
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1

Also Published As

Publication number Publication date
IL141494A0 (en) 2002-03-10
JP2002523028A (ja) 2002-07-30
NZ510002A (en) 2003-11-28
DE69933877D1 (de) 2006-12-14
ATE344043T1 (de) 2006-11-15
US6124131A (en) 2000-09-26
US20030176349A1 (en) 2003-09-18
AU5691499A (en) 2000-03-14
EP1107768A1 (de) 2001-06-20
DE69933877T2 (de) 2007-06-21
CA2340328A1 (en) 2000-03-02
EP1107768A4 (de) 2004-12-29
CA2340328C (en) 2011-06-21
AU758627B2 (en) 2003-03-27
IL141494A (en) 2009-05-04
WO2000010578A1 (en) 2000-03-02
US6562799B1 (en) 2003-05-13
NO20010920D0 (no) 2001-02-23
EP1107768B1 (de) 2006-11-02

Similar Documents

Publication Publication Date Title
NO20010920L (no) Stabil hypoksi induserbar faktor-1&lt;alfa&gt; og anvendelsesmetoder
ATE31625T1 (de) Pharmazeutisches mittel zur behandlung des diabetes mellitus.
Ingimarsson et al. Side effects of long-term treatment with human leukocyte interferon
DK1214937T3 (da) Terfenadincarboxylat og behandling af hudirritation
KR950700333A (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
LU91544I2 (fr) Alpha alglucosidase
LV10180A (lv) Farmaceitiska kompozicija
FI103180B (fi) Flurbiprofeenia sisältävien lääkkeiden valmistus kipujen ja/tai tulehd usten torjumiseksi eläimissä ja ihmisissä
EP0151989A3 (en) Means for the treatment of cardiac diseases
PT950057E (pt) Enantiomeros de 3-piridilo e sua utilizacao como analgesicos
DE68926679D1 (de) Physiologisch aktives polypeptid, rekombinantes plasmid, rekombinante mikrobielle zellen, medizinisches präparat sowie verfahren zur gewinnung des gereinigten polypeptids
KR950701226A (ko) C-키트 수용체의 리간드 및 그의 사용방법
ATE187642T1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
WO2003034996B1 (en) Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
DK0817646T3 (da) Fremgangsmåder til behandling af inflammation og præparater derfor
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
Silverman et al. Activation of herpes simplex following dermabrasion: report of a patient successfully treated with intravenous acyclovir and brief review of the literature
IT8224624A0 (it) Sale metilglucamminico del flurbiprofen dotato di attivita&#39;terapeutica e procedimento per lasua preparazione.
NO995692D0 (no) Nye BPC-peptidsalter med organbeskyttende aktivitet, metoden for deres fremstilling og deres anvendelse
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
DE69330809T2 (de) Therapeutisches Agens für Neutropenie
DK277387D0 (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
NO960866D0 (no) Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler
MooN et al. Infective gangrene surrounding an empyema wound treated with hyperbaric oxygen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application